AbClon Inc (174900) - Total Liabilities

Latest as of March 2026: ₩10.16 Billion KRW ≈ $6.88 Million USD

Based on the latest financial reports, AbClon Inc (174900) has total liabilities worth ₩10.16 Billion KRW (≈ $6.88 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore AbClon Inc (174900) net asset momentum to track the company's year-over-year net asset growth rate.

AbClon Inc - Total Liabilities Trend (2015–2025)

This chart illustrates how AbClon Inc's total liabilities have evolved over time, based on quarterly financial data. See AbClon Inc (174900) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.

AbClon Inc Competitors by Total Liabilities

The table below lists competitors of AbClon Inc ranked by their total liabilities.

Company Country Total Liabilities
Career Technology MFG Co Ltd
TW:6153
Taiwan NT$6.91 Billion
Jiangsu Sainty Corp Ltd
SHG:600287
China CN¥626.84 Million
Amarin Corporation PLC
NASDAQ:AMRN
USA $196.35 Million
WCM Beteiligungs- und Grundbesitz-AG
F:WCMK
Germany €54.32 Million
Fujian Cement Inc
SHG:600802
China CN¥2.55 Billion
Shenzhen Capol International & Associates Co Ltd
SHE:002949
China CN¥1.34 Billion
Suzhou Institute of Building Science Group Co Ltd
SHG:603183
China CN¥528.81 Million
Hefei Jingsong Intelligent Technology Co. Ltd. A
SHG:688251
China CN¥763.09 Million

Liability Composition Analysis (2015–2025)

This chart breaks down AbClon Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of AbClon Inc.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 4.89 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.17 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.15 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how AbClon Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for AbClon Inc (2015–2025)

The table below shows the annual total liabilities of AbClon Inc from 2015 to 2025.

Year Total Liabilities Change
2025-12-31 ₩10.31 Billion
≈ $6.99 Million
-45.10%
2024-12-31 ₩18.78 Billion
≈ $12.72 Million
+3.24%
2023-12-31 ₩18.19 Billion
≈ $12.33 Million
+4.18%
2022-12-31 ₩17.46 Billion
≈ $11.83 Million
+66.76%
2021-12-31 ₩10.47 Billion
≈ $7.09 Million
-3.07%
2020-12-31 ₩10.80 Billion
≈ $7.32 Million
-6.81%
2019-12-31 ₩11.59 Billion
≈ $7.85 Million
+15.84%
2018-12-31 ₩10.00 Billion
≈ $6.78 Million
+188.10%
2017-12-31 ₩3.47 Billion
≈ $2.35 Million
-13.84%
2016-12-31 ₩4.03 Billion
≈ $2.73 Million
+40.95%
2015-12-31 ₩2.86 Billion
≈ $1.94 Million
--

About AbClon Inc

KQ:174900 Korea Biotechnology
Market Cap
$296.40 Million
₩437.36 Billion KRW
Market Cap Rank
#14829 Global
#460 in Korea
Share Price
₩21950.00
Change (1 day)
+11.42%
52-Week Range
₩9890.00 - ₩89100.00
All Time High
₩90600.00
About

AbClon Inc. engages in the research and development of antibody drugs in South Korea and Sweden. The company's products in pipeline include NEST platform technology products for breast and gastric cancers; AffiMab platform technology products for colon cancer and autoimmune diseases; and CAR-T platform technology products for hematologic and ovarian cancers. AbClon Inc. was founded in 2010 and is… Read more